Side effects include:
Injection site reactions (erythema, pain/tenderness, swelling, pruritus, warmth, hematoma, induration), headache, extremity pain.

The most common adverse events were headache and injection site reactions.
Very common ( or more): Injection site pain (up to ), injection site erythema , injection site swelling , pruritus Common ( to ): Warmth, hematoma, indurationPostmarketing reports: Injection site rash, injection site urticaria, transient injection site lymphadenopathy
Common ( to ): Headache, asthenia
Common ( to ): Death, fever, asthenia
The most common reported cause of death was cardiovascular disease ( in the vaccine group,  in the placebo group).
The overall incidence of death occurring at any time during the study was similar between groups:  deaths  in the vaccine group and  deaths  in the placebo group.
Common ( to ): Congestive heart failure or pulmonary edema
Congestive heart failure or pulmonary edema occurred in  of patients receiving the vaccine versus  of patients receiving placebo in the AE monitoring substudy.
Common ( to ): Respiratory infection, flu syndrome, rhinitis, respiratory disorderVery rare (less than ): Asthma exacerbation
Common ( to ): DiarrheaPostmarketing reports: Nausea
Common ( to ): Skin disorderRare (less than ): Non-injection site varicella-type rash, non-injection site zoster-like rashPostmarketing reports: Rash
Common ( to ): Pain in extremityVery rare (less than ): Polymyalgia rheumaticaPostmarketing reports: Arthralgia, myalgia
Very rare (less than ): Anaphylactic reactionPostmarketing reports: Hypersensitivity reactions including anaphylactic reactions
Very rare (less than ): VaricellaPostmarketing reports: Herpes zoster (vaccine strain)
Frequency not reported: Lymphadenopathy
Postmarketing reports: Necrotizing retinitis (patients on immunosuppressive therapy)
It is possible that some side effects of Zostavax may not have been reported.
These can be reported to the FDA here.
Always consult a healthcare professional for medical advice.